Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.
Identifieur interne : 003173 ( Main/Exploration ); précédent : 003172; suivant : 003174Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.
Auteurs : Trisha F. Hue [États-Unis] ; Steven R. Cummings [États-Unis] ; Jane A. Cauley [États-Unis] ; Douglas C. Bauer [États-Unis] ; Kristine E. Ensrud ; Elizabeth Barrett-Connor [États-Unis] ; Dennis M. Black [États-Unis]Source :
- JAMA internal medicine [ 2168-6114 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Agents de maintien de la densité osseuse (administration et posologie), Agents de maintien de la densité osseuse (pharmacologie), Alendronate (administration et posologie), Alendronate (pharmacologie), Carcinome canalaire du sein, Diphosphonates (administration et posologie), Diphosphonates (pharmacologie), Femelle, Humains, Imidazoles (administration et posologie), Imidazoles (pharmacologie), Incidence, Méthode en double aveugle, Odds ratio, Perfusions veineuses, Post-ménopause, Risque, Sujet âgé, Sujet âgé de 80 ans ou plus, Tumeurs du sein (), Tumeurs du sein (anatomopathologie), Tumeurs du sein (épidémiologie), Tumeurs osseuses (), Tumeurs osseuses (secondaire), Études de suivi.
- MESH :
- administration et posologie : Agents de maintien de la densité osseuse, Alendronate, Diphosphonates, Imidazoles.
- anatomopathologie : Tumeurs du sein.
- pharmacologie : Agents de maintien de la densité osseuse, Alendronate, Diphosphonates, Imidazoles.
- secondaire : Tumeurs osseuses.
- épidémiologie : Tumeurs du sein.
- Adulte d'âge moyen, Carcinome canalaire du sein, Femelle, Humains, Incidence, Méthode en double aveugle, Odds ratio, Perfusions veineuses, Post-ménopause, Risque, Sujet âgé, Sujet âgé de 80 ans ou plus, Tumeurs du sein, Tumeurs osseuses, Études de suivi.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Alendronate (administration & dosage), Alendronate (pharmacology), Bone Density Conservation Agents (administration & dosage), Bone Density Conservation Agents (pharmacology), Bone Neoplasms (prevention & control), Bone Neoplasms (secondary), Breast Neoplasms (epidemiology), Breast Neoplasms (pathology), Breast Neoplasms (prevention & control), Carcinoma, Ductal, Breast, Diphosphonates (administration & dosage), Diphosphonates (pharmacology), Double-Blind Method, Female, Follow-Up Studies, Humans, Imidazoles (administration & dosage), Imidazoles (pharmacology), Incidence, Infusions, Intravenous, Middle Aged, Odds Ratio, Postmenopause, Risk.
- MESH :
- chemical , administration & dosage : Alendronate, Bone Density Conservation Agents, Diphosphonates, Imidazoles.
- chemical , pharmacology : Alendronate, Bone Density Conservation Agents, Diphosphonates, Imidazoles.
- epidemiology : Breast Neoplasms.
- pathology : Breast Neoplasms.
- prevention & control : Bone Neoplasms, Breast Neoplasms.
- secondary : Bone Neoplasms.
- Aged, Aged, 80 and over, Carcinoma, Ductal, Breast, Double-Blind Method, Female, Follow-Up Studies, Humans, Incidence, Infusions, Intravenous, Middle Aged, Odds Ratio, Postmenopause, Risk.
Abstract
Studies have shown that bisphosphonates may have antitumor and antimetastatic properties. Recently, observational studies have suggested a possible protective effect of bisphosphonates on breast cancer, but the effect of bisphosphonate use on risk of breast cancer has not been tested in randomized trials.
DOI: 10.1001/jamainternmed.2014.3634
PubMed: 25111880
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001919
- to stream PubMed, to step Curation: 001911
- to stream PubMed, to step Checkpoint: 001911
- to stream Ncbi, to step Merge: 002E83
- to stream Ncbi, to step Curation: 002E83
- to stream Ncbi, to step Checkpoint: 002E83
- to stream Main, to step Merge: 003320
- to stream Main, to step Curation: 003173
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.</title><author><name sortKey="Hue, Trisha F" sort="Hue, Trisha F" uniqKey="Hue T" first="Trisha F" last="Hue">Trisha F. Hue</name><affiliation wicri:level="3"><nlm:affiliation>San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California, San Francisco.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">San Francisco</settlement><region type="state">Californie</region></placeName><wicri:orgArea>San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California</wicri:orgArea></affiliation></author><author><name sortKey="Cummings, Steven R" sort="Cummings, Steven R" uniqKey="Cummings S" first="Steven R" last="Cummings">Steven R. Cummings</name><affiliation wicri:level="3"><nlm:affiliation>San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California, San Francisco2California Pacific Medical Center Research Institute, San Francisco.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">San Francisco</settlement><region type="state">Californie</region></placeName><wicri:orgArea>San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California, San Francisco2California Pacific Medical Center Research Institute</wicri:orgArea></affiliation></author><author><name sortKey="Cauley, Jane A" sort="Cauley, Jane A" uniqKey="Cauley J" first="Jane A" last="Cauley">Jane A. Cauley</name><affiliation wicri:level="2"><nlm:affiliation>Center for Aging and Population Health, Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Center for Aging and Population Health, Department of Epidemiology, University of Pittsburgh, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Bauer, Douglas C" sort="Bauer, Douglas C" uniqKey="Bauer D" first="Douglas C" last="Bauer">Douglas C. Bauer</name><affiliation wicri:level="3"><nlm:affiliation>San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California, San Francisco.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">San Francisco</settlement><region type="state">Californie</region></placeName><wicri:orgArea>San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California</wicri:orgArea></affiliation></author><author><name sortKey="Ensrud, Kristine E" sort="Ensrud, Kristine E" uniqKey="Ensrud K" first="Kristine E" last="Ensrud">Kristine E. Ensrud</name><affiliation><nlm:affiliation>Department of Medicine, University of Minnesota, Minneapolis.</nlm:affiliation><wicri:noCountry code="subField">Minneapolis</wicri:noCountry></affiliation></author><author><name sortKey="Barrett Connor, Elizabeth" sort="Barrett Connor, Elizabeth" uniqKey="Barrett Connor E" first="Elizabeth" last="Barrett-Connor">Elizabeth Barrett-Connor</name><affiliation wicri:level="3"><nlm:affiliation>Division of Epidemiology, Department of Family and Preventive Medicine, University of California, San Diego.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">San Diego</settlement><region type="state">Californie</region></placeName><wicri:orgArea>Division of Epidemiology, Department of Family and Preventive Medicine, University of California</wicri:orgArea></affiliation></author><author><name sortKey="Black, Dennis M" sort="Black, Dennis M" uniqKey="Black D" first="Dennis M" last="Black">Dennis M. Black</name><affiliation wicri:level="3"><nlm:affiliation>San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California, San Francisco.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">San Francisco</settlement><region type="state">Californie</region></placeName><wicri:orgArea>San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California</wicri:orgArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25111880</idno><idno type="pmid">25111880</idno><idno type="doi">10.1001/jamainternmed.2014.3634</idno><idno type="wicri:Area/PubMed/Corpus">001919</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001919</idno><idno type="wicri:Area/PubMed/Curation">001911</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001911</idno><idno type="wicri:Area/PubMed/Checkpoint">001911</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001911</idno><idno type="wicri:Area/Ncbi/Merge">002E83</idno><idno type="wicri:Area/Ncbi/Curation">002E83</idno><idno type="wicri:Area/Ncbi/Checkpoint">002E83</idno><idno type="wicri:Area/Main/Merge">003320</idno><idno type="wicri:Area/Main/Curation">003173</idno><idno type="wicri:Area/Main/Exploration">003173</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.</title><author><name sortKey="Hue, Trisha F" sort="Hue, Trisha F" uniqKey="Hue T" first="Trisha F" last="Hue">Trisha F. Hue</name><affiliation wicri:level="3"><nlm:affiliation>San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California, San Francisco.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">San Francisco</settlement><region type="state">Californie</region></placeName><wicri:orgArea>San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California</wicri:orgArea></affiliation></author><author><name sortKey="Cummings, Steven R" sort="Cummings, Steven R" uniqKey="Cummings S" first="Steven R" last="Cummings">Steven R. Cummings</name><affiliation wicri:level="3"><nlm:affiliation>San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California, San Francisco2California Pacific Medical Center Research Institute, San Francisco.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">San Francisco</settlement><region type="state">Californie</region></placeName><wicri:orgArea>San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California, San Francisco2California Pacific Medical Center Research Institute</wicri:orgArea></affiliation></author><author><name sortKey="Cauley, Jane A" sort="Cauley, Jane A" uniqKey="Cauley J" first="Jane A" last="Cauley">Jane A. Cauley</name><affiliation wicri:level="2"><nlm:affiliation>Center for Aging and Population Health, Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Center for Aging and Population Health, Department of Epidemiology, University of Pittsburgh, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Bauer, Douglas C" sort="Bauer, Douglas C" uniqKey="Bauer D" first="Douglas C" last="Bauer">Douglas C. Bauer</name><affiliation wicri:level="3"><nlm:affiliation>San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California, San Francisco.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">San Francisco</settlement><region type="state">Californie</region></placeName><wicri:orgArea>San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California</wicri:orgArea></affiliation></author><author><name sortKey="Ensrud, Kristine E" sort="Ensrud, Kristine E" uniqKey="Ensrud K" first="Kristine E" last="Ensrud">Kristine E. Ensrud</name><affiliation><nlm:affiliation>Department of Medicine, University of Minnesota, Minneapolis.</nlm:affiliation><wicri:noCountry code="subField">Minneapolis</wicri:noCountry></affiliation></author><author><name sortKey="Barrett Connor, Elizabeth" sort="Barrett Connor, Elizabeth" uniqKey="Barrett Connor E" first="Elizabeth" last="Barrett-Connor">Elizabeth Barrett-Connor</name><affiliation wicri:level="3"><nlm:affiliation>Division of Epidemiology, Department of Family and Preventive Medicine, University of California, San Diego.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">San Diego</settlement><region type="state">Californie</region></placeName><wicri:orgArea>Division of Epidemiology, Department of Family and Preventive Medicine, University of California</wicri:orgArea></affiliation></author><author><name sortKey="Black, Dennis M" sort="Black, Dennis M" uniqKey="Black D" first="Dennis M" last="Black">Dennis M. Black</name><affiliation wicri:level="3"><nlm:affiliation>San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California, San Francisco.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">San Francisco</settlement><region type="state">Californie</region></placeName><wicri:orgArea>San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California</wicri:orgArea></affiliation></author></analytic><series><title level="j">JAMA internal medicine</title><idno type="eISSN">2168-6114</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Alendronate (administration & dosage)</term><term>Alendronate (pharmacology)</term><term>Bone Density Conservation Agents (administration & dosage)</term><term>Bone Density Conservation Agents (pharmacology)</term><term>Bone Neoplasms (prevention & control)</term><term>Bone Neoplasms (secondary)</term><term>Breast Neoplasms (epidemiology)</term><term>Breast Neoplasms (pathology)</term><term>Breast Neoplasms (prevention & control)</term><term>Carcinoma, Ductal, Breast</term><term>Diphosphonates (administration & dosage)</term><term>Diphosphonates (pharmacology)</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Imidazoles (administration & dosage)</term><term>Imidazoles (pharmacology)</term><term>Incidence</term><term>Infusions, Intravenous</term><term>Middle Aged</term><term>Odds Ratio</term><term>Postmenopause</term><term>Risk</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Agents de maintien de la densité osseuse (administration et posologie)</term><term>Agents de maintien de la densité osseuse (pharmacologie)</term><term>Alendronate (administration et posologie)</term><term>Alendronate (pharmacologie)</term><term>Carcinome canalaire du sein</term><term>Diphosphonates (administration et posologie)</term><term>Diphosphonates (pharmacologie)</term><term>Femelle</term><term>Humains</term><term>Imidazoles (administration et posologie)</term><term>Imidazoles (pharmacologie)</term><term>Incidence</term><term>Méthode en double aveugle</term><term>Odds ratio</term><term>Perfusions veineuses</term><term>Post-ménopause</term><term>Risque</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tumeurs du sein ()</term><term>Tumeurs du sein (anatomopathologie)</term><term>Tumeurs du sein (épidémiologie)</term><term>Tumeurs osseuses ()</term><term>Tumeurs osseuses (secondaire)</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Alendronate</term><term>Bone Density Conservation Agents</term><term>Diphosphonates</term><term>Imidazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Alendronate</term><term>Bone Density Conservation Agents</term><term>Diphosphonates</term><term>Imidazoles</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents de maintien de la densité osseuse</term><term>Alendronate</term><term>Diphosphonates</term><term>Imidazoles</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agents de maintien de la densité osseuse</term><term>Alendronate</term><term>Diphosphonates</term><term>Imidazoles</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Bone Neoplasms</term><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Tumeurs osseuses</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Bone Neoplasms</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Carcinoma, Ductal, Breast</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Incidence</term><term>Infusions, Intravenous</term><term>Middle Aged</term><term>Odds Ratio</term><term>Postmenopause</term><term>Risk</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Carcinome canalaire du sein</term><term>Femelle</term><term>Humains</term><term>Incidence</term><term>Méthode en double aveugle</term><term>Odds ratio</term><term>Perfusions veineuses</term><term>Post-ménopause</term><term>Risque</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tumeurs du sein</term><term>Tumeurs osseuses</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Studies have shown that bisphosphonates may have antitumor and antimetastatic properties. Recently, observational studies have suggested a possible protective effect of bisphosphonates on breast cancer, but the effect of bisphosphonate use on risk of breast cancer has not been tested in randomized trials.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Pennsylvanie</li></region><settlement><li>San Diego</li><li>San Francisco</li></settlement></list><tree><noCountry><name sortKey="Ensrud, Kristine E" sort="Ensrud, Kristine E" uniqKey="Ensrud K" first="Kristine E" last="Ensrud">Kristine E. Ensrud</name></noCountry><country name="États-Unis"><region name="Californie"><name sortKey="Hue, Trisha F" sort="Hue, Trisha F" uniqKey="Hue T" first="Trisha F" last="Hue">Trisha F. Hue</name></region><name sortKey="Barrett Connor, Elizabeth" sort="Barrett Connor, Elizabeth" uniqKey="Barrett Connor E" first="Elizabeth" last="Barrett-Connor">Elizabeth Barrett-Connor</name><name sortKey="Bauer, Douglas C" sort="Bauer, Douglas C" uniqKey="Bauer D" first="Douglas C" last="Bauer">Douglas C. Bauer</name><name sortKey="Black, Dennis M" sort="Black, Dennis M" uniqKey="Black D" first="Dennis M" last="Black">Dennis M. Black</name><name sortKey="Cauley, Jane A" sort="Cauley, Jane A" uniqKey="Cauley J" first="Jane A" last="Cauley">Jane A. Cauley</name><name sortKey="Cummings, Steven R" sort="Cummings, Steven R" uniqKey="Cummings S" first="Steven R" last="Cummings">Steven R. Cummings</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003173 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003173 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25111880
|texte= Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25111880" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |